Korean Journal of Radiology

  • 제22권3호
  • /
  • Pages.425-434
  • /
  • 2021
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

The Prognostic Value of 18F-Fluorodeoxyglucose PET/CT in the Initial Assessment of Primary Tracheal Malignant Tumor: A Retrospective Study

  • Dan Shao (Department of PET Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences) ;
  • Qiang Gao (Department of Radiology, Guangzhou First People's Hospital) ;
  • You Cheng (Department of PET Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences) ;
  • Dong-Yang Du (School of Biomedical Engineering and Guangdong Provincial Key Laboratory of Medical Image Processing, Southern Medical University) ;
  • Si-Yun Wang (Department of PET Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences) ;
  • Shu-Xia Wang (Department of PET Center, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences)
  • 투고 : 2020.03.02
  • 심사 : 2020.07.01
  • 발행 : 2021.03.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To investigate the potential value of 18F-fluorodeoxyglucose (FDG) PET/CT in predicting the survival of patients with primary tracheal malignant tumors. Materials and Methods: An analysis of FDG PET/CT findings in 37 primary tracheal malignant tumor patients with a median follow-up period of 43.2 months (range, 10.8-143.2 months) was performed. Cox proportional hazards regression analyses were used to assess the associations between quantitative 18F-FDG PET/CT parameters, other clinic-pathological factors, and overall survival (OS). A risk prognosis model was established according to the independent prognostic factors identified on multivariate analysis. A survival curve determined by the Kaplan-Meier method was used to assess whether the prognosis prediction model could effectively stratify patients with different risks factors. Results: The median survival time of the 37 patients with tracheal tumors was 38.0 months, with a 95% confidence interval of 10.8 to 65.2 months. The 3-year, 5-year and 10-year survival rate were 54.1%, 43.2%, and 16.2%, respectively. The metabolic tumor volume (MTV), total lesion glycolysis (TLG), maximum standardized uptake value, age, pathological type, extension categories, and lymph node stage were included in multivariate analyses. Multivariate analysis showed MTV (p = 0.011), TLG (p = 0.020), pathological type (p = 0.037), and extension categories (p = 0.038) were independent prognostic factors for OS. Additionally, assessment of the survival curve using the Kaplan-Meier method showed that our prognosis prediction model can effectively stratify patients with different risks factors (p < 0.001). Conclusion: This study shows that 18F-FDG PET/CT can predict the survival of patients with primary tracheal malignant tumors. Patients with an MTV > 5.19, a TLG > 16.94 on PET/CT scans, squamous cell carcinoma, and non-E1 were more likely to have a reduced OS.

키워드

과제정보

This work was supported by grants from the Joint Funds of Basic and Applied Basic Research Foundation of Guangdong Province of China (2019A1515110377), Guangdong Medical Research Foundation (A2019340) and Guangdong Science and Technology Department (2017ZC0250).

참고문헌

  1. Meyers BF, Mathisen DJ. Management of tracheal neoplasms. Oncologist 1997;2:245-253 
  2. Azar T, Abdul-Karim FW, Tucker HM. Adenoid cystic carcinoma of the trachea. Laryngoscope 1998;108:1297-1300 
  3. Urdaneta AI, Yu JB, Wilson LD. Population based cancer registry analysis of primary tracheal carcinoma. Am J Clin Oncol 2011;34:32-37 
  4. Nouraei SM, Middleton SE, Nouraei SA, Virk JS, George PJ, Hayward M, et al. Management and prognosis of primary tracheal cancer: a national analysis. Laryngoscope 2014;124:145-150 
  5. Yang KY, Chen YM, Huang MH, Perng RP. Revisit of primary malignant neoplasms of the trachea: clinical characteristics and survival analysis. Jpn J Clin Oncol 1997;27:305-309 
  6. Weber AL, Shortsleeve M, Goodman M, Montgomery W, Grillo HC. Cartilaginous tumors of the larynx and trachea. Radiol Clin North Am 1978;16:261-267 
  7. Wood DE. Management of malignant tracheobronchial obstruction. Surg Clin North Am 2002;82:621-642 
  8. Bhattacharyya N. Contemporary staging and prognosis for primary tracheal malignancies: a population-based analysis. Otolaryngol Head Neck Surg 2004;131:639-642 
  9. He J, Shen J, Huang J, Dai C, Liang W, Ye M, et al. Prognosis of primary tracheal tumor: a population-based analysis. J Surg Oncol 2017;115:1004-1010 
  10. Macchiarini P. Primary tracheal tumours. Lancet Oncol 2006;7:83-91 
  11. Rehman S, Lovvorn HN 3rd, Rickman OB, Wootten CT, Chinnadurai S. Unique application of awake tracheoscopy and endobronchial ultrasound in the management of tracheal mucoepidermoid carcinoma. Head Neck 2018;40:E58-E61 
  12. Chow DC, Komaki R, Libshitz HI, Mountain CF, Ellerbroek N. Treatment of primary neoplasms of the trachea. The role of radiation therapy. Cancer 1993;71:2946-2952 
  13. Maziak DE, Todd TR, Keshavjee SH, Winton TL, Van Nostrand P, Pearson FG. Adenoid cystic carcinoma of the airway: thirty-two-year experience. J Thorac Cardiovasc Surg 1996;112:1522-1532 
  14. Luick ML, Hansen EK, Greenberg MS, Kim R, Owens M, Moore CJ, et al. Primary tracheal non-Hodgkin's lymphoma. J Clin Oncol 2011;29:e193-e195 
  15. Agrawal S, Jackson C, Celie KB, Dodhia C, Monie D, Monzon J, et al. Survival trends in patients with tracheal carcinoma from 1973 to 2011. Am J Otolaryngol 2017;38:673-677 
  16. Wang SY, Wang SX, Liao JQ, Chen G. 18F-FDG PET/CT and contrast-enhanced CT of primary malignant tracheal tumor. Clin Nucl Med 2016;41:595-605 
  17. Regnard JF, Fourquier P, Levasseur P. Results and prognostic factors in resections of primary tracheal tumors: a multicenter retrospective study. The French Society of Cardiovascular Surgery. J Thorac Cardiovasc Surg 1996;111:808-814